Tagged with Deloitte

Vaccines Public trust in the COVID-19 supply chain has grown, but there is still a strong need for standards, processes, and capabilities to ensure patients across the globe have access to lifesaving therapies. A secure and equitable supply chain is a factor in expanding access and building trust.  A new report…

Global The research evidence is unequivocal, public, planetary and economic health are inextricably linked and no continent, country or community is immune from the impacts of climate change. The race to net zero is also a race to a healthier, cleaner and more resilient future. Giles Dean, Sustainability Manager at Deloitte…

Singapore Ashish Mahajan, Partner in Deloitte’s Life Sciences and Healthcare Consulting Practice in Southeast Asia, outlines some of the key trends playing out in the region, the extent to which the COVID-19 pandemic has sped up the industry’s digitalisation efforts, and how Asian innovation stands to develop in the coming years.…

Global The vital importance of robust supply chains and distribution networks has been foregrounded over the past year as the world struggled to ensure supply of PPE, medicines, diagnostics, and vaccines to fight the COVID-19 pandemic. With logistics and distribution now at the forefront of the global pharma conversation, key players…

deloitte Vaccines       BACK TO HOME Securing Trust in the COVID-19 Supply Chain: From Development & Delivery to Acceptance & Administration Scientists have come together in an unparalleled worldwide collaboration and sharing of data to advance a COVID-19 vaccine.[1] As rollouts become reality, stakeholders from across the globe will need…

Global Scientists have come together in an unparalleled worldwide collaboration and sharing of data to advance a COVID-19 vaccine.[1] As rollouts become reality, stakeholders from across the globe will need to collaborate to ensure these vaccines are available and accepted. Vaccines will need a high level of trust for a return…

USA Joe Lewis outlines the key concerns of Deloitte’s pharma clients around manufacturing and supply chain operations in the wake of the COVID-19 pandemic, how companies can come out of the crisis stronger, and highlights some of the major issues surrounding vaccine allocation and deployment.   One of the most common…

Global During the FT Global Pharmaceutical and Biotechnology Conference earlier this week, four Big Pharma and biotech executives spoke about the changing power structure of the industry and the factors driving the evolution of the pharma innovation model. The session was moderated by Deloitte global life sciences and health care leader…

Cell & Gene Therapy Deloitte’s Omkar Kawalekar, Hussain Mooraj, and Amit Agarwal examine the evolution and future of cell and gene therapy manufacturing and the areas in which biopharma firms need to invest in order to succeed in this emergent field.   Cell and gene therapies (CGT) are the next evolution of personalized health…

Global Greg Reh leads Deloitte’s global life sciences sector which includes clients in biopharma, medtech, generics and distribution businesses, as well as non-profit patient advocacy organizations and regulatory agencies. He discusses talent acquisition and retention in global life sciences today, the challenges around data and AI uptake, and the future of…

China 2019 was a landmark year for the Chinese healthcare industry.* Since the publication of the ‘Healthy China 2030’ blueprint in 2016 by the Chinese government, the entire sector has been virtually turned upside down. Against the warm backdrop of regulatory support, a series of policy changes were unveiled in the…

Webinar With the recent publication of Ten years on: Measuring the Return from Pharmaceutical Innovation 2019, PharmaBoardroom has teamed up with Deloitte to offer its readers an exclusive webinar on The Future of Biopharma.   On 25th February 2020, join us to discuss the major trends that have impacted the biopharma industry over the past ten years, the…